NO20014852L - Melanomterapi - Google Patents

Melanomterapi

Info

Publication number
NO20014852L
NO20014852L NO20014852A NO20014852A NO20014852L NO 20014852 L NO20014852 L NO 20014852L NO 20014852 A NO20014852 A NO 20014852A NO 20014852 A NO20014852 A NO 20014852A NO 20014852 L NO20014852 L NO 20014852L
Authority
NO
Norway
Prior art keywords
melanoma therapy
melanoma
therapy
Prior art date
Application number
NO20014852A
Other languages
English (en)
Other versions
NO20014852D0 (no
NO328111B1 (no
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014852D0 publication Critical patent/NO20014852D0/no
Publication of NO20014852L publication Critical patent/NO20014852L/no
Publication of NO328111B1 publication Critical patent/NO328111B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20014852A 1999-04-08 2001-10-05 Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet. NO328111B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08
PCT/US2000/009129 WO2000061175A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha in melanoma therapy

Publications (3)

Publication Number Publication Date
NO20014852D0 NO20014852D0 (no) 2001-10-05
NO20014852L true NO20014852L (no) 2001-12-06
NO328111B1 NO328111B1 (no) 2009-12-07

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014852A NO328111B1 (no) 1999-04-08 2001-10-05 Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet.

Country Status (21)

Country Link
EP (3) EP1535622B1 (no)
JP (1) JP2000319195A (no)
CN (1) CN1390132A (no)
AR (1) AR023398A1 (no)
AT (3) ATE496631T1 (no)
AU (1) AU771569B2 (no)
BR (1) BR0009646A (no)
CA (1) CA2303992A1 (no)
CO (1) CO5170404A1 (no)
CY (1) CY1108922T1 (no)
DE (3) DE60045591D1 (no)
DK (2) DK1535622T3 (no)
ES (2) ES2319776T3 (no)
HU (1) HU230057B1 (no)
MY (1) MY126763A (no)
NO (1) NO328111B1 (no)
PE (1) PE20010027A1 (no)
PT (2) PT1043026E (no)
TW (1) TWI292320B (no)
WO (1) WO2000061175A2 (no)
ZA (1) ZA200108173B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
HK1032349A1 (en) 2001-07-20
AU771569B2 (en) 2004-03-25
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
ES2239954T3 (es) 2005-10-16
EP1043026B1 (en) 2005-06-01
DE60045591D1 (de) 2011-03-10
PT1535622E (pt) 2009-03-19
ZA200108173B (en) 2003-01-06
EP1043026A3 (en) 2000-12-20
BR0009646A (pt) 2002-02-05
EP1535622B1 (en) 2008-12-31
AU4204600A (en) 2000-11-14
EP1043026A2 (en) 2000-10-11
TWI292320B (en) 2008-01-11
HU230057B1 (hu) 2015-06-29
EP2025344B1 (en) 2011-01-26
DK1043026T3 (da) 2005-07-04
NO20014852D0 (no) 2001-10-05
NO328111B1 (no) 2009-12-07
DE60020444T2 (de) 2006-05-04
MY126763A (en) 2006-10-31
DE60020444D1 (de) 2005-07-07
ATE496631T1 (de) 2011-02-15
PE20010027A1 (es) 2001-02-05
WO2000061175A3 (en) 2001-02-01
HK1075416A1 (en) 2005-12-16
JP2000319195A (ja) 2000-11-21
CO5170404A1 (es) 2002-06-27
DK1535622T3 (da) 2009-04-20
AR023398A1 (es) 2002-09-04
ATE419001T1 (de) 2009-01-15
ATE296639T1 (de) 2005-06-15
HUP0200775A3 (en) 2002-09-30
WO2000061175A2 (en) 2000-10-19
CN1390132A (zh) 2003-01-08
CA2303992A1 (en) 2000-10-08
ES2319776T3 (es) 2009-05-12
PT1043026E (pt) 2005-09-30
EP2025344A1 (en) 2009-02-18
DE60041290D1 (de) 2009-02-12
EP1535622A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
DK1637127T3 (da) Terapeutisk mikroskum
DE69924365D1 (de) Massagegerät
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE60017816D1 (de) Herzschrittmacher
DE69916133D1 (de) Elektro-neuro-adaptiver stimulator
DE60016600D1 (de) Herzschrittmacher
DE59911113D1 (de) Herzschrittmacher
DE50015795D1 (de) Sektionaltor
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE60013608D1 (de) Herzschrittmacher
DE50003259D1 (de) Textilie
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE60016452D1 (de) Herzschrittmacher
ATE440824T1 (de) Nitro-sulfobenzamide
DE10082008D2 (de) Ausbeulgerät
DK1535622T3 (da) Melanomterapi
ATA203199A (de) Ablauf
DE50002156D1 (de) Azofarbstoffmischungen
DE10085167T1 (de) Gangumschalteinrichtung

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees